Asian Pacific Journal of Cancer Prevention

  • 제13권10호
  • /
  • Pages.5263-5272
  • /
  • 2012
  • /
  • 1513-7368(pISSN)
  • /
  • 2476-762X(eISSN)
아시아태평양암예방학회 (Asian Pacific Journal of Cancer Prevention)
권호 표지
DOI QR코드

DOI QR Code

Chinese Patients with Gastric Cancer Need Targeted Adjuvant Chemotherapy Schemes

  • Shi, Wen-Tao (Dept. of Oncology, Zhongnan Hospital, Hubei Key Laboratory of Tumor Biological Behavior, Hubei Cancer Clinical Study Center) ;
  • Wei, Lei (Dept. of Oncology, Zhongnan Hospital, Hubei Key Laboratory of Tumor Biological Behavior, Hubei Cancer Clinical Study Center) ;
  • Xiang, Jin (Dept. of Pathology and Pathophysiology, Hubei Provincial Key Laboratory of Allergy and Immune-Related Diseases Centre for Medical Research, Research Center of Food and Drug Evaluation) ;
  • Su, Ke (Dept. of Oncology, Zhongnan Hospital, Hubei Key Laboratory of Tumor Biological Behavior, Hubei Cancer Clinical Study Center) ;
  • Ding, Qiong (Dept. of Oncology, Zhongnan Hospital, Hubei Key Laboratory of Tumor Biological Behavior, Hubei Cancer Clinical Study Center) ;
  • Tang, Meng-Jie (Dept. of Oncology, Zhongnan Hospital, Hubei Key Laboratory of Tumor Biological Behavior, Hubei Cancer Clinical Study Center) ;
  • Li, Ji-Qiang (Dept. of Pathology and Pathophysiology, Hubei Provincial Key Laboratory of Allergy and Immune-Related Diseases Centre for Medical Research, Research Center of Food and Drug Evaluation) ;
  • Guo, Yi (Dept. of Epidemiology, School of Medicine, Wuhan University) ;
  • Wang, Pu (Dept. of Rehabilitation, Zhongnan Hospital, Wuhan University) ;
  • Zhang, Jing-Wei (Dept. of Oncology, Zhongnan Hospital, Hubei Key Laboratory of Tumor Biological Behavior, Hubei Cancer Clinical Study Center)
  • 발행 : 2012.10.31
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Background: Gastric cancer (GC) is one of the most common cancers in China. Adjuvant chemotherapy (AC) is a routine auxiliary treatment for GC recommended by the guidelines issued in 2011 by the Ministry of Health of the People's Republic of China, but the relevant credible consequences in China have been insufficient because of China's late start and ethical concerns. Methods: A series of databases, including Cochrane Library, MEDLINE, EMBASE, the Chinese database of the National Knowledge Infrastructure and the VIP database, were searched by 2 reviewers independently for studies investigating AC for GC through March 2012. The retrieved literature was screened according to the eligibility criteria. Results: A total of 35 randomized control trials (RCTs) were subjected to the final analysis, including 4,043 patients in treatment group and 3,884 in the control group, as well as 4 clinical-control trials (CCTs), which accessed the final analysis with 238 and 252 patients, respectively. AC reduced the risk of death as a protective treatment with statistical significance (HR=0.91, 95%CI: [0.85, 0.97], P=0.002), and it seemed more effective for Asian than non-Asian patients. The effects of AC were not influenced by the starting time (P>0.05). D2 lymphadenectomy-based chemotherapy was effective (HR=0.89, 95%CI: [0.80, 0.99], P=0.04). Oral S-1 40 mg/m2 after D2 lymphadenectomy might be a better choice for Asians with advanced GC and might result in a greater reduction of adverse events than in non-Asian patients. GRADE quality assessment determined that the strength of the evidence from foreign studies from Europe, the United States and Asian countries other than China was high, while it was moderate for Chinese studies. Conclusion: AC was effective or even curative in Chinese patients in general, although it is still necessary to optimize a targeted AC scheme for Chinese patients with GC.

키워드

참고문헌

  1. Ajani JA, Rodriguez W, Bodoky G, et al (2010). Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial. J Clin Oncol, 28, 1547-53. https://doi.org/10.1200/JCO.2009.25.4706
  2. Al-Batran SE, Hartmann JT, Probst S, et al (2008). Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol, 26, 1435-42. https://doi.org/10.1200/JCO.2007.13.9378
  3. Allum WH, Hallissey MT, Kelly KA (1989a). Adjuvant chemotherapy in operable gastric cancer. 5 year follow-up of first British Stomach Cancer Group trial. Lancet, 1, 571-4.
  4. Allum WH, Hallissey MT, Ward LC, Hockey MS (1989b). A controlled, prospective, randomised trial of adjuvant chemotherapy or radiotherapy in resectable gastric cancer: interim report. British Stomach Cancer Group. Br J Cancer, 60, 739-44. https://doi.org/10.1038/bjc.1989.350
  5. Bajetta E, Buzzoni R, Mariani L, et al (2002). Adjuvant chemotherapy in gastric cancer: 5-year results of a randomised study by the Italian Trials in Medical Oncology (ITMO) Group. Ann Oncol, 13, 299-307. https://doi.org/10.1093/annonc/mdf040
  6. Bonenkamp JJ, Hermans J, Sasako M, et al (1999). Extended lymph-node dissection for gastric cancer. N Engl J Med, 340, 908-14. https://doi.org/10.1056/NEJM199903253401202
  7. Bonfani G (1988). Adjuvant treatments following curative resection for gastric cancer. Br J Surg, 75, 1100-4. https://doi.org/10.1002/bjs.1800751117
  8. Bouche O, Ychou M, Burtin P, et al (2005). Adjuvant chemotherapy with 5-fluorouracil and cisplatin compared with surgery alone for gastric cancer: 7-year results of the FFCD randomized phase III trial (8801). Ann Oncol, 16, 1488-97. https://doi.org/10.1093/annonc/mdi270
  9. Chen Z. Report of the third national mortality retrospective sampling survey. Beijing: Peking Union Medical College Press; 2008.
  10. Chipponi J, Huguier M, Pezet D, et al (2004). Randomized trial of adjuvant chemotherapy after curative resection for gastric cancer. Am J Surg, 187, 440-5. https://doi.org/10.1016/j.amjsurg.2003.12.014
  11. Cirera L, Balil A, Batiste-Alentorn E, et al (1999). Randomized clinical trial of adjuvant mitomycin plus tegafur in patients with resected stage III gastric cancer. J Clin Oncol, 17, 3810-5.
  12. Coombes RC, Schein PS, Chilvers CE, et al (1990). A randomized trial comparing adjuvant fluorouracil, doxorubicin, and mitomycin with no treatment in operable gastric cancer. International Collaborative Cancer Group. J Clin Oncol, 8, 1362-9.
  13. Cuschieri A, Weeden S, Fielding J, et al (1999). Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Surgical Cooperative Group. Br J Cancer, 79, 1522-30. https://doi.org/10.1038/sj.bjc.6690243
  14. De Vita F, Giuliani F, Orditura M, et al (2007). Adjuvant chemotherapy with epirubicin, leucovorin, 5-fluorouracil and etoposide regimen in resected gastric cancer patients: a randomized phase III trial by the Gruppo Oncologico Italia Meridionale (GOIM 9602 Study). Ann Oncol, 18, 1354-8. https://doi.org/10.1093/annonc/mdm128
  15. Di Costanzo F, Gasperoni S, Manzione L, et al (2008). Adjuvant chemotherapy in completely resected gastric cancer: a randomized phase III trial conducted by GOIRC. J Natl Cancer Inst, 100, 388-98. https://doi.org/10.1093/jnci/djn054
  16. Douglass HO Jr. (1982). Controlled trial of adjuvant chemotherapy following curative resection for gastric cancer. The Gastrointestinal Tumor Study Group. Cancer, 49, 1116-22. https://doi.org/10.1002/1097-0142(19820315)49:6<1116::AID-CNCR2820490609>3.0.CO;2-U
  17. Engstrom PF, Lavin PT, Douglass HO, Jr., Brunner KW (1985). Postoperative adjuvant 5-fluorouracil plus methyl-CCNU therapy for gastric cancer patients. Cooperative Oncology Group study (EST 3275). Cancer, 55, 1868-73. https://doi.org/10.1002/1097-0142(19850501)55:9<1868::AID-CNCR2820550904>3.0.CO;2-B
  18. Estape J, Grau JJ, Lcobendas F, et al (1991). Mitomycin C as an adjuvant treatment to resected gastric cancer. A 10-year follow-up. Ann Surg, 213, 219-21. https://doi.org/10.1097/00000658-199103000-00006
  19. Fujimoto S, Takahashi M, Mutou T, Kobayashi K, Toyosawa T (1999). Successful intraperitoneal hyperthermic chemoperfusion for the prevention of postoperative peritoneal recurrence in patients with advanced gastric carcinoma. Cancer, 85, 529-34. https://doi.org/10.1002/(SICI)1097-0142(19990201)85:3<529::AID-CNCR3>3.0.CO;2-9
  20. Grau JJ, Estape J, Alcobendas F, Pera C, Daniels M, Teres J (1993). Positive results of adjuvant mitomycin-C in resected gastric cancer: a randomised trial on 134 patients. Eur J Cancer, 29A, 340-2.
  21. Guyatt G, Oxman AD, Akl EA, et al (2011a). GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol, 64, 383-94. https://doi.org/10.1016/j.jclinepi.2010.04.026
  22. Guyatt GH, Oxman AD, Schunemann HJ, Tugwell P, Knottnerus A (2011b). GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology. J Clin Epidemiol, 64, 380-2. https://doi.org/10.1016/j.jclinepi.2010.09.011
  23. Hallissey MT, Dunn JA, Ward LC, Allum WH (1994). The second British Stomach Cancer Group trial of adjuvant radiotherapy or chemotherapy in resectable gastric cancer: five-year follow-up. Lancet, 343, 1309-12. https://doi.org/10.1016/S0140-6736(94)92464-3
  24. Hamazoe R, Maeta M, Kaibara N (1994). Intraperitoneal thermochemotherapy for prevention of peritoneal recurrence of gastric cancer. Final results of a randomized controlled study. Cancer, 73, 2048-52. https://doi.org/10.1002/1097-0142(19940415)73:8<2048::AID-CNCR2820730806>3.0.CO;2-Q
  25. Hartgrink HH, van de Velde CJ, Putter H, et al (2004). Neoadjuvant chemotherapy for operable gastric cancer: long term results of the Dutch randomised FAMTX trial. Eur J Surg Oncol, 30 ,643-9. https://doi.org/10.1016/j.ejso.2004.04.013
  26. Higgins JP, Altman DG, Sterne JA. Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011) 2011.
  27. Kang YK, Kang WK, Shin DB, et al (2009). Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. Ann Oncol, 20, 666-73. https://doi.org/10.1093/annonc/mdn717
  28. Kobayakawa M, Kojima Y (2011). Tegafur/gimeracil/oteracil (S-1) approved for the treatment of advanced gastric cancer in adults when given in combination with cisplatin: a review comparing it with other fluoropyrimidine-based therapies. Onco Targets Ther, 4, 193-201.
  29. Krook JE, O'Connell MJ, Wieand HS, et al (1991). A prospective, randomized evaluation of intensive-course 5-fluorouracil plus doxorubicin as surgical adjuvant chemotherapy for resected gastric cancer. Cancer, 67, 2454-8. https://doi.org/10.1002/1097-0142(19910515)67:10<2454::AID-CNCR2820671010>3.0.CO;2-2
  30. Kulig J, Kolodziejczyk P, Sierzega M, et al (2010). Adjuvant chemotherapy with etoposide, adriamycin and cisplatin compared with surgery alone in the treatment of gastric cancer: a phase III randomized, multicenter, clinical trial. Oncology, 78, 54-61. https://doi.org/10.1159/000292360
  31. Li DZ, Zhao YT, Song Z (2009). Effects of FOLFOX4 neoadjuvant chemotherapy protocol on advanced gastric cancer. J Xinxiang Med College, 26, 170-2.
  32. Lise M, Nitti D, Marchet A, et al (1995). Final results of a phase III clinical trial of adjuvant chemotherapy with the modified fluorouracil, doxorubicin, and mitomycin regimen in resectable gastric cancer. J Clin Oncol, 13, 2757-63.
  33. Macdonald JS, Fleming TR, Peterson RF, et al (1995). Adjuvant chemotherapy with 5-FU, adriamycin, and mitomycin-C (FAM) versus surgery alone for patients with locally advanced gastric adenocarcinoma: A Southwest Oncology Group study. Ann Surg Oncol, 2, 488-94. https://doi.org/10.1007/BF02307081
  34. Nakajima T, Fukami A, Takagi K, Kajitani T (1980). Adjuvant chemotherapy with mitomycin C, and with a multi-drug combination of mitomycin C, 5-fluorouracil and cytosine arabinoside after curative resection of gastric cancer. Jap J Clin Oncol, 10, 187.
  35. Nakajima T, Takahashi T, Takagi K, Kuno K, Kajitani T (1984). Comparison of 5-fluorouracil with ftorafur in adjuvant chemotherapies with combined inductive and maintenance therapies for gastric cancer. J Clin Oncol, 2, 1366-71.
  36. Nakajima T, Nashimoto A, Kitamura M, et al (1999). Adjuvant mitomycin and fluorouracil followed by oral uracil plus tegafur in serosa-negative gastric cancer: a randomised trial. Gastric Cancer Surgical Study Group. Lancet, 354, 273-7. https://doi.org/10.1016/S0140-6736(99)01048-X
  37. Nakajima T, Kinoshita T, Nashimoto A, et al (2007). Randomized controlled trial of adjuvant uracil-tegafur versus surgery alone for serosa-negative, locally advanced gastric cancer. Br J Surg, 94, 1468-76. https://doi.org/10.1002/bjs.5996
  38. Nashimoto A, Nakajima T, Furukawa H, et al (2003). Randomized trial of adjuvant chemotherapy with mitomycin, Fluorouracil, and Cytosine arabinoside followed by oral Fluorouracil in serosa-negative gastric cancer: Japan Clinical Oncology Group 9206-1. J Clin Oncol, 21, 2282-7. https://doi.org/10.1200/JCO.2003.06.103
  39. Neri B, Cini G, Andreoli F, et al (2001). Randomized trial of adjuvant chemotherapy versus control after curative resection for gastric cancer: 5-year follow-up. Br J Cancer, 84, 878-80. https://doi.org/10.1054/bjoc.2000.1472
  40. Nitti D, Wils J, Dos Santos JG, et al (2006). Randomized phase III trials of adjuvant FAMTX or FEMTX compared with surgery alone in resected gastric cancer. A combined analysis of the EORTC GI Group and the ICCG. Ann Oncol, 17, 262-9.
  41. Panzini I, Gianni L, Fattori PP, et al (2002). Adjuvant chemotherapy in gastric cancer: a meta-analysis of randomized trials and a comparison with previous meta-analyses. Tumori, 88, 21-7.
  42. Paoletti X, Oba K, Burzykowski T, et al (2010). Benefit of adjuvant chemotherapy for resectable gastric cancer: a metaanalysis. JAMA, 303, 1729-37. https://doi.org/10.1001/jama.2010.534
  43. Parmar MK, Torri V, Stewart L (1998). Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med, 17, 2815-34. https://doi.org/10.1002/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8
  44. Sakuramoto S, Sasako M, Yamaguchi T, et al (2007). Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med, 357, 1810-20. https://doi.org/10.1056/NEJMoa072252
  45. Sautner T, Hofbauer F, Depisch D, Schiessel R, Jakesz R (1994). Adjuvant intraperitoneal cisplatin chemotherapy does not improve long-term survival after surgery for advanced gastric cancer. J Clin Oncol, 12, 970-4.
  46. Schlag P (1987). Adjuvant chemotherapy in gastric cancer. World J Surg, 11, 473-7. https://doi.org/10.1007/BF01655812
  47. Scott NW, McPherson GC, Ramsay CR, Campbell MK (2002). The method of minimization for allocation to clinical trials. a review. Control Clin Trials, 23, 662-74. https://doi.org/10.1016/S0197-2456(02)00242-8
  48. Takahashi T, Hagiwara A, Shimotsuma M, Sawai K, Yamaguchi T (1995). Prophylaxis and treatment of peritoneal carcinomatosis: intraperitoneal chemotherapy with mitomycin C bound to activated carbon particles. World J Surg, 19, 565-9. https://doi.org/10.1007/BF00294724
  49. Tentes AA, Markakidis SK, Karanikiotis C, et al (2006). Intraarterial chemotherapy as an adjuvant treatment in locally advanced gastric cancer. Langenbecks Arch Surg, 391, 124-9. https://doi.org/10.1007/s00423-006-0022-z
  50. Tsavaris N, Tentas K, Kosmidis P, et al (1996). A randomized trial comparing adjuvant fluorouracil, epirubicin, and mitomycin with no treatment in operable gastric cancer. Chemotherapy, 42, 220-6. https://doi.org/10.1159/000239446
  51. Yang Y, Xu Q, Huang YN, Yang SJ, Du P (2010). Clinical study of intraperitoneal injection of sapylin combined with intraperitoneal hyperchemic hypo-osmolar infusion during radical gastrectomy. Mod Oncol, 18, 1340-2.
  52. Yu W, Whang I, Chung HY, Averbach A, Sugarbaker PH (2001). Indications for early postoperative intraperitoneal chemotherapy of advanced gastric cancer: results of a prospective randomized trial. World J Surg, 25, 985-90. https://doi.org/10.1007/s00268-001-0067-7
  53. Zhang YQ, Xu HM (2005). Analysis and evaluation for the effect of postoperative introperitoneal chemotherapy in gastric cancer. Chin J Clin Oncol, 32, 38-41.
  54. Zhou JW, Zhou Y, Luo ZF, et al (2011). Adjuvant chemotherapy of teniposide combined with oxaliplatin and 5-fluorouracil for resected gastric carcinoma. J Chin Pract Diagn Ther, 25, 641-3.
  55. Zhou XN, Sun XB, Chen WQ, et al (2012). Analysis of incidence and mortality of stomach cancer in China from 2003 to 2007. Tumor, 32, 109-14.

피인용 문헌

  1. miR-34a regulates cisplatin-induce gastric cancer cell death by modulating PI3K/AKT/survivin pathway vol.35, pp.2, 2014, https://doi.org/10.1007/s13277-013-1171-7
  2. Naringenin inhibits proliferation, migration, and invasion as well as induces apoptosis of gastric cancer SGC7901 cell line by downregulation of AKT pathway vol.37, pp.8, 2016, https://doi.org/10.1007/s13277-016-5013-2
  3. Cantharidin induces G2/M phase arrest and apoptosis in human gastric cancer SGC-7901 and BGC-823 cells vol.8, pp.6, 2014, https://doi.org/10.3892/ol.2014.2611